menu

Loading...

SXTC Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

2.330

Open

2.240

VWAP

2.24

Vol

24.18K

Mkt Cap

2.15M

Low

2.150

Amount

54.17K

EV/EBITDA(TTM)

--

Total Shares

957.96K

EV

-17.93M

EV/OCF(TTM)

--

P/S(TTM)

0.59

China SXT Pharmaceuticals Inc is a holding company principally engaged in the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (TCMP). TCMP is a type of Chinese Traditional Medicine (TCM) products. The Company sells three types of TCMP products: Advanced TCMP, Fine TCMP and Regular TCMP. The Company sells its products under the brand Suxuantang. The Company mainly operates its businesses in the domestic market.

Show More

Events Timeline

(ET)

2026-01-15

09:20:00

China SXT Pharmaceuticals Launches AI Initiative to Enhance TCM Supply Chain

2026-01-09 (ET)

2026-01-09

15:00:00

China SXT Pharmaceuticals Enters Agreement to Sell 66.67M Shares

2026-01-08 (ET)

2026-01-08

16:30:00

Major Averages Mixed as Oil Prices Surge Nearly 4%

2026-01-08

12:00:00

Major Averages Mixed Near Noon as Investors Reassess 2026 Optimism

2026-01-08

09:30:00

China SXT Pharmaceuticals Launches Strategic AI Insights Initiative

2025-03-17 (ET)

2025-03-17

08:33:45

China SXT Pharmaceuticals regains compliance with Nasdaq

2024-10-07 (ET)

2024-10-07

16:20:38

China SXT Pharmaceuticals receives noncompliance notification from Nasdaq

News

Benzinga

DarkIris Inc Reports 27.3% Revenue Growth, Shares Surge

stocktwits

01-30stocktwits

China SXT Pharmaceuticals Announces 1-for-150 Reverse Stock Split to Boost Share Price

seekingalpha

01-30seekingalpha

China SXT Pharmaceuticals Announces 1-for-150 Share Consolidation

Newsfilter

01-30Newsfilter

China SXT Pharmaceuticals Announces Share Consolidation

Benzinga

Biomx Inc Shares Surge After 13D Filing Reveals Major Stake

Benzinga

Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%

Valuation Metrics

The current forward P/E ratio for China SXT Pharmaceuticals Inc (SXTC.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess China SXT Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding SXTC

Trading Trends

People Also Watch

Frequently Asked Questions

What is China SXT Pharmaceuticals Inc (SXTC) stock price today?

The current price of SXTC is 2.24 USD — it has decreased -1.75

What is China SXT Pharmaceuticals Inc (SXTC)'s business?

China SXT Pharmaceuticals Inc is a holding company principally engaged in the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (TCMP). TCMP is a type of Chinese Traditional Medicine (TCM) products. The Company sells three types of TCMP products: Advanced TCMP, Fine TCMP and Regular TCMP. The Company sells its products under the brand Suxuantang. The Company mainly operates its businesses in the domestic market.

What is the price predicton of SXTC Stock?

Wall Street analysts forecast SXTC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SXTC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is China SXT Pharmaceuticals Inc (SXTC)'s revenue for the last quarter?

China SXT Pharmaceuticals Inc revenue for the last quarter amounts to NaN USD, decreased

What is China SXT Pharmaceuticals Inc (SXTC)'s earnings per share (EPS) for the last quarter?

China SXT Pharmaceuticals Inc. EPS for the last quarter amounts to USD, decreased

How many employees does China SXT Pharmaceuticals Inc (SXTC). have?

China SXT Pharmaceuticals Inc (SXTC) has 75 emplpoyees as of March 02 2026.

What is China SXT Pharmaceuticals Inc (SXTC) market cap?

Today SXTC has the market capitalization of 2.15M USD.